PlanA.Earth: HV Capital and Keen Venture Partners invest USD 10 million in Plan A
3.11.2021 09:40:45 CET | news aktuell GmbH | Pressemelding
Berlin, 03 November 2021. Greentech start-up Plan A, the leading platform of science-based tools for carbon accounting, decarbonisation, and ESG management, has successfully closed its Series A funding round. European venture capital firm HV Capital is leading the USD 10 million round in the German company jointly with Netherlands-based Keen Venture Partners, with existing investors Demeter IM and coparion doubling down on its seed investment. Plan A will use the capital to further develop its platform and expand internationally with the opening of international hubs.
Certified provider builds on software's unique ESG capabilities
To help companies meet the ever-increasing societal and regulatory pressures, Plan A is further deepening its SaaS platform's calculation engine and machine learning capabilities, as well as expanding the decarbonisation tooling and Scope 3 calculations for various industries. In addition to the existing software functionalities for detailed corporate carbon footprint accounting and AI-driven decarbonisation planning, Plan A is launching an ESG tool for measuring, analysing, and reporting to address all existing and upcoming regulations.
International clients such as BMW, Société Générale, JOKR, Apax, and the European Union already rely on Plan A's software for complex carbon accounting and ESG measurement and improvement. They also count on the company’s strong scientific roots and Plan A’s carbon accounting team consisting of international scientists, researchers, and experts in emissions accounting, carbon reduction, sustainability and lifecycle analysis.
Focus on further internationalisation
Opening new offices in Paris and Munich in 2021, Plan A is already well underway in its international expansion strategy, with a goal of becoming a fully global company in the next three years.
Please download the entire press release, quotes, and high-res imagery here.
Press contact
Matthias Grünewald
Senior PR Manager
T. +49 157 5140 6386
E. press@plana.earth
W. plana.earth
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich16.7.2026 10:42:31 CEST | Press release
Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients
They’re really going for it: emporia launches the first 5G smartphone with a screen warranty15.7.2026 08:40:22 CEST | Press release
Better safe than sorry: the emporiaSMART.8 with Smartcover and rubber protectors
FEV collaborates with Microsoft on efficient AI model approach for in car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities built on NVIDIA GPU-accelerated compute and AI model microservices. The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release
SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:37:04 CEST | Press release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom
